$0.89
3.66% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US88875G1013
Symbol
TLSA
Sector
Industry

Tiziana Life Sciences PLC Sponsored ADR Stock price

$0.89
-0.03 3.21% 1M
+0.26 40.24% 6M
+0.33 59.02% YTD
+0.34 60.45% 1Y
-0.53 37.29% 3Y
-0.24 21.10% 5Y
-0.76 45.96% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.03 3.66%
ISIN
US88875G1013
Symbol
TLSA
Sector
Industry

Key metrics

Market capitalization $93.86m
Enterprise Value $76.11m
EV/FCF (TTM) EV/FCF negative
Short interest 0.38%

Is Tiziana Life Sciences PLC Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Tiziana Life Sciences PLC Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Tiziana Life Sciences PLC Sponsored ADR:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Tiziana Life Sciences PLC Sponsored ADR:

Buy
100%

Financial data from Tiziana Life Sciences PLC Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Annually
Dec '22
+/-
%
- -
-
100%
- Direct Costs 0.05 0.05
64% 64%
-
-0.05 -0.05
64% 64%
-
- Selling and Administrative Expenses 4.71 4.71
70% 70%
-
- Research and Development Expense 13 13
2% 2%
-
-18 -18
39% 39%
-
- Depreciation and Amortization 0.05 0.05
64% 64%
-
EBIT (Operating Income) EBIT -18 -18
39% 39%
-
Net Profit -15 -15
34% 34%
-

In millions USD.

Don't miss a Thing! We will send you all news about Tiziana Life Sciences PLC Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tiziana Life Sciences PLC Sponsored ADR Stock News

Positive
Proactive Investors
14 days ago
Tiziana Life Sciences Ltd (NASDAQ:TLSA) this week announced positive research findings showing the anti-inflammatory potential of the company's nasal anti-CD3 antibody foralumab when used in combination with semaglutide, a GLP-1 agonist marketed as Ozempic and Wegovy. CEO Ivor Elrifi joined Proactive to discuss the findings.
Positive
Proactive Investors
14 days ago
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it will participate in the upcoming BIO-Europe 2024 conference in Stockholm. The event will allow Tiziana to engage with industry leaders, potential collaborators, and investors, emphasizing its recent clinical advancements, particularly data from its combination study involving Ozempic, a GLP-1 agonist.
Neutral
GlobeNewsWire
14 days ago
NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced its participation in the BIO-Europe 2024 conference, taking place November 4-6 in Sto...
More Tiziana Life Sciences PLC Sponsored ADR News

Company Profile

Tiziana Life Sciences Plc is a biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. Its lead product candidate in immunology is Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody. The company was founded by Gabriele Marco Antonio Cerrone on November 4, 2013 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Ivor Elrifi
Founded 1998
Website www.tizianalifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today